Peringatan Keamanan

Tavaborole is generally well tolerated with most adverse events reported as mild and not related to treatment. Treatment related adverse events that occurred in >1 % of participants include application site exfoliation, application site erythema, and application site dermatitis, and ingrown toenail.

Tavaborole

DB09041

small molecule approved investigational

Deskripsi

Tavaborale is a novel, boron-based topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed due to *Trichophyton rubrum* or *Trichophyton mentagrophytes* infection. Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu).

Struktur Molekul 2D

Berat 151.93
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 28.5 hr
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

7.5%. Subungual onychomycosis is difficult to treat due to the poorly perfused location of the infection in the nailbed. To be effective, a topical treatment must penetrate the nail plate and reach the site of infection at a concentration sufficient to exert anti-fungal activity. Tavaborole was shown to produce anti-fungal effects after 5 days of topical administration.

Metabolisme

Tavaborole undergoes extensive metabolism. Metabolite profiling revealed trace levels of a sulfated-conjugate and a benzoic acid metabolite, consistent with the known biotransformation of tavaborole.

Rute Eliminasi

Primarily renal.

Interaksi Obat

0 Data
Tidak ada data.

Target Protein

leucine--tRNA ligase

Referensi & Sumber

Artikel (PubMed)
  • PMID: 25226015
    Toledo-Bahena ME, Bucko A, Ocampo-Candiani J, Herz-Ruelas ME, Jones TM, Jarratt MT, Pollak RA, Zane LT: The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis. J Drugs Dermatol. 2014 Sep;13(9):1124-32.
  • PMID: 25118637
    Markham A: Tavaborole: first global approval. Drugs. 2014 Sep;74(13):1555-8. doi: 10.1007/s40265-014-0276-7.

Contoh Produk & Brand

Produk: 16 • International brands: 0
Produk
  • Kerydin
    Solution • 43.5 mg/1mL • Topical • US • Approved
  • Kerydin
    Solution • 43.5 mg/1mL • Topical • US • Approved
  • Tavaborole
    Solution • 43.5 mg/1mL • Topical • US • Generic • Approved
  • Tavaborole
    Solution • 43.5 mg/1mL • Topical • US • Generic • Approved
  • Tavaborole
    Solution • 43.5 mg/1mL • Topical • US • Generic • Approved
  • Tavaborole
    Solution • 43.5 mg/1mL • Topical • US • Generic • Approved
  • Tavaborole
    Solution • 43.5 mg/1mL • Topical • US • Generic • Approved
  • Tavaborole
    Solution • 43.5 mg/1mL • Topical • US • Generic • Approved
Menampilkan 8 dari 16 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul